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Both apolipoprotein E (apoE) and 24(S)-
hydroxycholesterol are involved in the 
pathogenesis of Alzheimer's disease (AD). 
It has been hypothesized that apoE affects 
AD development via isoform-specific 
effects on lipid trafficking between 
astrocytes and neurons. However, the 
regulation of the cholesterol supply of 
neurons via apoE-containing high density 
lipoproteins (HDL) remains to be 
clarified. We show, for the first time, that 
the brain-specific metabolite of 
cholesterol produced by neurons, i.e. 
24(S)-hydroxycholesterol induces apoE 
transcription, protein synthesis and 
secretion in a dose- and time-dependent 
manner in cells of astrocytic but not of 
neuronal origin. Moreover, 24(S)-
hydroxycholesterol primes astrocytoma, 
but not neuroblastoma cells, to mediate 
cholesterol efflux to apoE. Similar results 
were obtained using the synthetic Liver-
X-Receptor (LXR) agonist GW683965A, 
suggesting involvement of an LXR-
controlled signalling pathway. A 10- to 
20-fold higher basal LXR  and   
expression level in astrocytoma compared 
to neuroblastoma cells may underlie these 
differential effects. Furthermore, apoE-
mediated cholesterol efflux from 
astrocytoma cells may be controlled by 
the ATP-binding cassette transporters 
ABCA1 and ABCG1, since their 
expression was also upregulated by both 
compounds. In contrast, ABCG4 seems 
not to be involved, as its expression was 
induced only in neuronal cells. The 
expression of SREBP-2, LDLR, 
HMGCoA-Reductase and SREBP-1c was 
transiently upregulated by GW683965A 
in astrocytes, but down-regulated by 
24(S)-hydroxycholesterol, suggesting that 
cholesterol efflux and synthesis are 
regulated independently. In conclusion, 
evidence is provided that 24(S)-
hydroxycholesterol induces apoE-
mediated efflux of cholesterol in 
astrocytes via an LXR-controlled 
pathway, which may be relevant for 
chronic and acute neurological diseases.  
 
Disturbances in brain cholesterol 
homeostasis are associated with the onset of 
severe neurological diseases (1) and have 
recently been suggested to play a key role in 
the development of Alzheimer's disease 
(AD) (2,3). The brain, although comprising 
just 2% of the total body mass, contains 
about a quarter of an individual's whole 
body unesterified cholesterol. Brain 
cholesterol originates almost exclusively 
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from in situ neosynthesis (1): circulating 
cholesterol is prevented from entering the 
brain by the blood-brain-barrier (4). Since 
cholesterol cannot be degraded and is 
neurotoxic at high levels, excess cholesterol 
is secreted from the brain into the circulation 
(5). Cholesterol is removed from the brain 
predominantly (about 60%) in the form of 
the relatively polar brain-specific metabolite 
24(S)-hydroxycholesterol formed by the 
enzyme cholesterol 24(S)-hydroxylase 
(CYP46) (1). The remaining 40% of 
cholesterol is secreted from the brain via an 
unknown pathway which may involve apoE 
(6). CYP46 is expressed predominantly by 
neurons (7,8). Several studies have 
suggested a role for 24(S)-
hydroxycholesterol in the pathogenesis of 
AD (9-11). Polymorphisms of CYP46 have 
been linked to AD and the expression of this 
enzyme appeared to be shifted from neurons 
to glia in AD patients (12). Finally, 
increased levels of 24(S)-hydroxycholesterol 
levels have been detected in cerebrospinal 
fluid of AD patients (13).   
24(S)-hydroxycholesterol is a 
natural ligand of the Liver-X-receptors 
(LXR), which have recently been identified 
as central players in the regulation of 
cholesterol metabolism (14,15). LXR belong 
to the nuclear hormone receptor superfamily 
and two isoforms, i.e., LXR and LXR, 
have been identified that are activated by 
oxysterols. Both isoforms of LXR are 
expressed in the central nervous system (16) 
and are thought to be involved in the 
regulation of brain cholesterol metabolism. 
LXR/-null mice show a variety of CNS 
defects upon aging, including lipid 
accumulation, astrocyte proliferation and 
disorganized myelin sheaths (17). The 
synthetic LXR ligand T0901317 was found 
to induce the expression of apoE and of the 
ATP-binding cassette transporters A1 
(ABCA1) and G1 (ABCG1) in astrocytes 
(18). However, reported in vivo effects of 
T0901317 on apoE expression in mouse 
brain are inconsistent (16,19,20).  
The strongest genetic risk factor 
known for sporadic AD is apolipoprotein E4 
(apoE4), one of the three common apoE 
variants (apoE2, apoE3, apoE4) in humans 
(21,22). ApoE is a key player in the 
transport of cholesterol in the circulation 
(23) and is also thought to fulfil such a role 
within the brain (24). Astrocytes are the 
predominant source of apoE in the brain. 
These cells secrete apoE in association with 
cholesterol and phospholipids in the form of 
small, high-density lipoprotein (HDL)-like 
particles (25). It has been suggested that 
these particles provide neurons with 
cholesterol required for the formation of 
new membranes, e.g., during development, 
regeneration after injury or during the 
formation of new synaptic contacts (26). It 
has been hypothesized that apoE may affect 
the pathogenesis of AD by isoform-specific 
effects on lipid trafficking between 
astrocytes and neurons (27). Indeed, apoE in 
combination with cholesterol, induces the 
outgrowth of neurites in an isoform-specific 
manner in neuronal cultures (28). However, 
factors that regulate the supply of glial-
derived apoE-containing lipoproteins are 
poorly understood.  
In this study, we tested the 
hypothesis that 24(S)-hydroxycholesterol 
represents a natural brain-specific LXR 
ligand that is involved in the regulation of 
the apoE-mediated lipid supply. For this 
purpose, the effects of 24(S)-
hydroxycholesterol and the synthetic LXR 
agonist GW683965A on the expression of 
APOE and additional LXR target genes 
involved in cholesterol efflux were 
compared using human neuroblastoma- and 
astrocytoma cell lines, as well as primary 
astrocytes. We found that 24(S)-
hydroxycholesterol, like GW683965A, is 
able to induce the expression of ABCA1, 
ABCG1, and APOE in astrocytes, and to 
elevate apoE-mediated cholesterol efflux in 
astrocytoma but not in neuroblastoma cells.  
Our observations support the hypothesis that 
24(S)-hydroxycholesterol participates in an 
LXR-controlled pathway that regulates 
cholesterol availability in the brain. 
 
EXPERIMENTAL PROCEDURES 
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Chemical Reagents: 24(S)-
hydroxycholesterol was a kind gift from Dr. 
D. Lutjohann (Bonn University, Germany), 
22(R)-hydroxycholesterol was a kind gift 
from Dr. J.Plat (Maastricht University, The 
Netherlands). GW683965A was provided by 
GlaxoSmithKline Pharmaceuticals 
(Stevenage, UK). The following reagents 
were purchased from Sigma (St. Louis, MO, 
USA): 9-cis-retinoic acid (RA), leupeptin, 
aprotinin, phenylmethylsulphonylfluoride 
(PMSF), bovine insulin, human transferrin, 
putrescine, sodium selenite and 
progesterone. ApoA-I and apoE were 
purchased from Calbiochem (VWR 
International BV, The Netherlands). Stocks 
of 24(S)-OH cholesterol (10mM), 22(R)-OH 
cholesterol (10mM) and cholesterol (10mM) 
were dissolved in ethanol. GW683965A 
(2mM) and RA (10mM) were dissolved in 
DMSO. 
Cell Culture Experiments: The human 
astrocytoma cell line CCF-STTG1 and 
human neuroblastoma cell line SH-SY-5Y 
were purchased from European Collection 
of Cell Cultures (CACC) (Salisbury, UK). 
CCF-STTG1 and SH-SY-5Y cells were 
cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) with 10% FCS. At 80-
90% confluency, cells were washed with 
phosphate-buffered saline (PBS) and treated 
with different reagents in DMEM/HamF12 
(1:1) with 10% FCS for various periods of 
time as indicated. SH-SY-5Y cells were 
preincubated for 24 hours in the DMEM-
HamF12 (1:1) medium without serum 
containing N2 supplement (2.5 mg/mL 
bovine insulin, 10 mg/ml human transferrin 
(iron-saturated), 0.52 μg/mL sodium 
selenite, 1.61 mg/ml putrescine, 0.63 μg/mL 
progesterone in phosphate buffered saline 
(PBS), pH 7.3). At the end of the treatments, 
conditioned media were collected and the 
cells were either lysed in RIPA buffer (Santa 
Cruz, CA, USA) or total RNA was isolated 
as described below for subsequent analyses. 
 The method of rat primary astrocytes 
culturing was similar to published 
procedures (29,30). Neonatal (postnatal day 
1) Lewis rat pups, bred in the animal 
facilities of Maastricht University, were 
decapitated and the neocortex was dissected 
and cleared of meninges. The tissue was 
diced in small fragments and incubated in 
trypsin (0.05% in phosphate-buffered saline) 
at 37 °C for 15 min. Trypsinization was 
stopped by adding culture medium and the 
tissue was gently centrifuged. The 
supernatant was discarded and the pellet was 
resuspended in 1 ml culture medium. Single 
cell dissociation was achieved by three to 
five passes through a 5-ml pipette (Greiner, 
Germany) and 10–20 passes through a 1-ml 
pipette (Greiner). Then, the tissue was 
centrifuged very briefly to separate cells 
from tissue debris. The supernatant 
containing the cells was then plated into 
25 cm
2
 cell culture flasks (Corning, NY, 
USA) at a density of 10
6
 cells per flask. 
Culture medium was refreshed after 4–5 
days and every 2 days thereafter. At DIV12 
(days in vitro), the cultures reached 
confluence, and contaminating cells were 
shaken off on a rotary shaker (Rotofix 32, 
Hettich Zentrifugen). This involves shaking 
of the flasks for 48h and refreshment of the 
medium. At DIV14 the purification is 
complete, and renders >95% GFAP 
immunopositive astrocyte cultures. 
 Primary murine mixed glial cultures 
were prepared from postnatal day 1-2 
C57Bl/6 mice.  Brains from individual 
animals were placed into ice-cold Hanks 
Buffered Salt Solution (Canadian Life 
Technologies) containing 6 mg/ml glucose 
and 10 mM HEPES. Meninges were 
removed, frontal cortices were dissected and 
cells were dissociated by repeated passage 
through a series of wide to fine bored 
pipettes.  Dissociated cells were plated in 
DMEM (Canadian Life Technologies) with 
10% fetal bovine serum (FBS), 2 mM L-
glutamine (Canadian Life Technologies) and 
100 units/ml of penicillin-streptomycin 
(Canadian Life Technologies) at one 24-well 
plate per mouse.  Cells were cultured in the 
presence of 5% CO2 for 12 days, when cells 
were confluent and contained at least 80% 
astrocytes. Cells were treated with either 
vehicle only (Ethanol) or increasing 
concentrations of 24(S)-hydroxycholesterol 
for 24 h. Subsequently, cells were washed 
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once with phosphate buffered saline, 
harvested and lysed using a buffer 
containing 10% glycerol, 1% TritonX-100 
and protease inhibitor (Roche) in phosphate 
buffered saline (PBS).  Protein concentration 
was determined by Dc Protein Assay 
(BioRad). 
Western blot analysis: Cell lysates (25 μg 
protein/lane) or conditioned media 
concentrates (concentrated using Microcon
®
 
centrifugal filter device, Millipore, Billerica, 
MA, USA) were subjected to dodecyl 
sulfate-10 or 12% polyacrylamide gel 
electrophoresis (SDS-PAGE) and then 
transferred to Protran nitrocellulose transfer 
membranes (Schleicher & Schuell 
BioScience GmbH, Dassel, Germany) or to 
polyvinylidene (PVDF) membrane 
(Millipore). After blocking with 5% non-fat 
dry milk (Protifar-plus, Nutricia Netherland 
B.V.) in washing buffer (PBS with 0.5% 
Triton-X100), the membranes were 
incubated with antibodies against human 
apoE (1:500, DAKO A/S, Denmark), murine 
apoE (Santa Cruz), human glutamine 
synthetase (GS) (1:500, Transduction 
laboratories, Lexington, KY), GAPDH 
(Chemicon), or a monoclonal anti-ABCA1 
antibody raised against the second 
nucleotide binding domain (NBD2 of 
ABCA1) (31), overnight at 4°C. The 
membranes were then incubated with 
peroxidase-conjugated secondary antibodies, 
after which the results were visualized using 
ECL reagents (Amersham Biosciences, 
Little Chalfont) and autoradiography (LAS 
3000, Fuji Photo Film Co., Ltd, Japan). 
Bands were quantitated by densitometry 
using NIH Image J. 
RNA isolation and Real-time quantitative 
PCR (QRT-PCR) procedures: Total RNA 
was isolated using the Trizol method 
(Invitrogen, Breda, The Netherlands) 
according to the manufacturer’s instructions. 
Integrity of RNA was checked by agarose 
gel electrophoresis, and RNA concentration 
was measured spectrophotometrically 
(NanoDrop, Witec AG, Littau, Germany).  
Real-time quantitative PCR was performed 
using an Applied Biosystems 7700 sequence 
detector with 1.6.3 software (Perk-Elmer 
Corp., Foster City, CA, USA) as previously 
described (32) with modifications (33). 
Primer sequences are available upon request. 
Primers were obtained from Invitrogen 
(Breda, The Netherlands). Fluorogenic 
probes, labeled with 6-carboxy-fluorescein 
(FAM) and 6-carboxy-tetramethyl-
rhodamine (TAMRA), were made by 
Eurogentec (Seraing, Belgium).  
Efflux studies: CCF-STTG1 or SH-SY-5Y 
cells were cultured in DMEM/HamF12 (1:1) 
supplemented with 10% fetal calf serum. 
After washing with DMEM/HamF12 (1:1), 
cells were loaded with 30 g/ml 
[3H]cholesterol (38 Ci/mmol) in 
DMEM/HamF12 (1:1) supplemented with 
10% fetal calf serum for 24 h in the presence 
or absence of 24(S)-hydroxycholesterol or 
GW683965A. After cells were washed five 
times with PBS-BSA 0.2% (w/v), the efflux 
assay was started by adding 2.5 g/ml apoE 
or 5 g/ml apoA-I in DMEM/HamF12 (1:1) 
to the wells. After 20 h incubation at 37°C, 
the medium was collected and centrifuged. 
Subsequently, [3H]cholesterol was 
quantified in the supernatant by liquid 
scintillation counting. Total cellular 
[3H]cholesterol was determined after 
extraction of the cells with 2-propanol. The 
percentage efflux was calculated by dividing 
the radioactive counts in the efflux medium 
by the sum of the counts in the medium and 
the cell extract.  
Statistical analysis: Values are presented as 
mean ±standard deviation (SD). Statistical 
significance was determined by comparing 
means using an unpaired Student’s t-test, 
Mann-Whytney U-test and one-way 
ANOVA with Newman-Keuls post-test. A 
value of P< 0.05 was considered statistically 
significant. 
 
RESULTS 
 
The natural LXR ligand 24(S)-
hydroxycholesterol induces apoE gene 
expression and protein levels in 
astrocytoma cells and in primary 
astrocytes, but not in neuroblastoma cells. 
To determine the effect of the natural LXR-
ligand 24(S)-hydroxycholesterol on apoE 
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expression in astrocytoma- and 
neuroblastoma cells and in primary 
astrocytes, cells were incubated with 
increasing amounts of the compound. We 
found that the incubation with 24(S)-
hydroxycholesterol resulted a dose-
dependent increase of APOE mRNA levels 
in astrocytoma cells (CCF-STTG1), but 
failed to induce APOE expression in 
neuroblastoma cells (SH-SY-5Y) even after 
72 hours of incubation (Fig. 1A). The 
synthetic LXR agonist GW683965A (4 μM) 
also clearly induced APOE expression in 
astrocytoma cells, but not in neuroblastoma 
cells (Fig. 1A), strongly suggesting that 
24(S)-hydroxycholesterol exerts its effects 
via the LXR pathway. Importantly, 24(S)-
hydroxycholesterol also induced APOE gene 
expression in primary rat astrocytes in a 
dose dependent manner (Fig. 1B), 
supporting the physiological relevance of 
this process. 
The induction of APOE expression 
(Fig. 2A) by 24(S)-hydroxycholesterol and 
GW683965A in astrocytoma cells also 
appeared to be time-dependent, with strong 
induction already occurring after 24 hours 
and a steady increase up to 72 hours of 
incubation. The established LXR target gene 
SREBP-1c was also induced by both 
compounds, but displayed a different 
induction profile compared to apoE (Fig. 
2B). The expression of APOD, another 
LXR-target gene which has been suggested 
to compensate cholesterol transport 
functions in the absence of APOE (34), was 
not affected by the natural or synthetic LXR 
ligand in either cell line (data not shown). 
Next we determined if induction of APOE 
mRNA upregulation resulted in increased 
protein levels. As shown in Fig. 3A, cellular 
apoE protein levels in astrocytoma cells 
were also clearly upregulated by 24(S)-
hydroxycholesterol in a concentration-
dependent manner. Upon incubation of the 
cells for increasing periods of time in the 
presence of 10 μM of 24(S)-
hydroxycholesterol, apoE protein levels 
increased up to 48 hours and remained fairly 
constant thereafter up to 72 hours (Fig. 3B). 
Similar to 24(S)-hydroxycholesterol, the 
synthetic LXR agonist GW683965A 
increased apoE protein levels in astrocytoma 
cells in a concentration- and time-dependent 
manner (Fig. 3C,D). Secretion of apoE by 
astrocytoma cells into the medium was also 
strongly induced by 24(S)-
hydroxycholesterol and GW683965A in a 
concentration-dependent manner (Fig. 3E). 
24(S)-hydroxycholesterol also upregulated 
cellular apoE protein levels in murine 
primary mixed glial cultures containing 
>80% astrocytes (Fig. 3F), further 
substantiating our findings.  
Since differences in expression of 
LXRs may underlie the differential effects 
of 24(S)-hydroxycholesterol and 
GW683965A in the two cell types we next 
determined their basal expression levels. 
Significantly higher mRNA levels of LXR 
and LXR were found in astrocytoma cells 
compared to neuroblastoma cells (Fig. 4). 
Also SREBP-1c, an established LXR-target 
gene involved in cholesterol and fatty acid 
metabolism (35), was expressed 
predominantly in astrocytoma cells. In 
contrast, mRNA levels of SREBP-2, another 
transcription factor involved in control of 
cholesterol metabolism, were similar in both 
cells types (Fig. 4A). Primary rat astrocytes 
also displayed a similar transcription profile 
for these genes (Fig. 4B).  
 
24(S)-Hydroxycholesterol is a stronger 
regulator of intracellular apoE protein 
levels in astrocytoma cells than retinoic 
acid (RA) and free cholesterol.  
24(S)-Hydroxycholesterol was 
compared with other natural LXR/RXR 
ligands with respect to its effect on 
intracellular apoE levels. In accordance with 
the observation that brain apoE is 
predominantly synthesized by astrocytes 
(36,37), we observed that the basal 
expression of the APOE gene in  
astrocytoma cells was substantially higher 
than in neuroblastoma cells (Fig. 4A). In 
astrocytoma cells, 24(S)-hydroxycholesterol 
and GW683965A are as potent as 22R-
hydroxycholesterol in inducing intracellular 
and secreted apoE, and were considerably 
more effective than retinoic acid or free 
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cholesterol (Fig. 5A,C). Neither 24(S)-
hydroxycholesterol nor GW683965A, or any 
of the other LXR/RXR agonists affected 
apoE synthesis in neuroblastoma cells (Fig. 
5B), demonstrating that LXR-mediated 
upregulation of apoE synthesis and secretion 
is a pathway specific to astrocytes.  
 
24(S)-Hydroxycholesterol and 
GW683965A regulate the expression of 
ABC transporters and other genes related 
to cholesterol metabolism in a cell type-
specific manner.  
ABCA1, ABCG1 and ABCG4 are 
transporters of cholesterol and/or 
phospholipids from cells to extracellular 
acceptors that may also be involved in 
intercellular lipid transport within the brain 
(38,39). Since all three transporters have 
been identified as LXR target genes present 
in the brain (40,41), we examined the effects 
of 24(S)-hydroxycholesterol and 
GW683965A on their expression. The 
results presented in Fig. 6A shows that basal 
expression of ABCG1 mRNA was 
comparable in astrocytoma cells and in 
neuroblastoma cells. The relative expression 
of ABCA1 mRNA was higher than that of 
ABCG1  and  also 3-fold higher in 
neuroblastoma than in astrocytoma cells. 
Likewise, the basal relative expression of 
ABCG4 mRNA was significantly higher in 
SH-SY-5Y cells than in astrocytoma cells 
(Fig. 6A). A pattern of relative ABC 
transporter expression similar to that in 
astrocytoma cells was found in primary rat 
astrocytes (Fig. 6B) Incubation with 24(S)-
hydroxycholesterol resulted in a dose-
dependent upregulation of the expression of 
ABCA1 mRNA in astrocytoma, in 
neuroblastoma cells (Fig. 6C) and in 
primary astrocytes (Fig. 6D). In contrast, 
GW683965A induced ABCA1 mRNA only 
in astrocytoma cells and rat primary 
astrocytes (Fig. 6C, D). Furthermore, 24(S)-
hydroxycholesterol increased ABCA1 
protein levels in murine primary glia (Fig. 
6E). 
ABCG1 mRNA was strongly 
induced by both 24(S)-hydroxycholesterol 
and GW683965A in astrocytoma cells (Fig. 
6F), and primary astrocytes also 
demonstrated a significant induction of 
ABCG1 mRNA (Fig.6G).  In contrast, 
ABCG1 was unresponsive to either 
compound in neuroblastoma cells (Fig. 6F).  
Interestingly, ABCG4 was slightly 
upregulated by 24(S)-hydroxycholesterol 
but not by GW683965A in neuroblastoma 
cells, whereas this gene was not affected, or 
even slightly down-regulated, in 
astrocytoma cells and in primary astrocytes 
(Fig. 6H, I). Effects of 24(S)-
hydroxycholesterol and GW68395A on the 
expression of the ABC transporters 
mentioned were maximal at 24 hours of 
incubation in astrocytoma cells (data not 
shown).  
Next we determined the effect of 
24(S)-hydroxycholesterol or GW683965A 
on mRNA levels of other genes involved in 
cholesterol and/or fatty acid metabolism. 
Incubation of astrocytoma cells with 24(S)-
hydroxycholesterol resulted in a transient 
down-regulation of SREBP-2, LDLR and 
HMGCoA-R mRNA levels.  In contrast, 
GW683965A induced a transient increase in 
the expression of these genes with a 
maximal effect at 24 hours (Fig. 7). SR-BI 
expression in astrocytoma cells was not 
affected by either compound (data not 
shown). Additionally, neither 24(S)-
hydroxycholesterol nor GW683965A 
detectably affected the expression of 
SREBP-2, HMG-CoA-R and LDLR  in 
neuroblastoma cells (data not shown).  
 
24(S)-Hydroxycholesterol enhances apoE- 
and apoA-I-mediated cholesterol efflux 
from astrocytoma cells, while only the 
apoA-I-mediated cholesterol efflux from 
neuroblastoma is enhanced. 
We observed that basal cholesterol 
efflux from astrocytoma cells was higher 
than from neuroblastoma cells 
(approximately 4% compared to 0.5%, 
respectively, Fig. 8).  The addition of 24(S)-
hydroxycholesterol induced apoE- and 
apoA-I-mediated cholesterol efflux from 
astrocytoma cells to equivalent levels (Fig. 
8A), and similar effects were observed with 
synthetic LXR agonist GW683965A. 
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Interestingly, neither compound affected 
apoE-mediated cholesterol efflux from 
neuroblastoma cells (Fig. 8B), but rather 
specifically induced apoA-I-mediated 
cholesterol efflux from neuroblastoma cells 
(Fig. 8) 
 
 
DISCUSSION 
 
In this paper we addressed the regulation of 
genes involved in apoE-mediated cholesterol 
trafficking between astrocytes and neurons, 
an important process during regeneration 
and synaptic plasticity (25). We observe that 
24(S)-hydroxycholesterol is capable of 
inducing apoE and ABC transporter 
expression in astrocytic cells, as well as in 
primary rat and murine astrocytes.  In 
contrast, 24(S)-hydroxycholesterol did not 
induce expression of these genes in 
SHSY5Y neuronal cells. Notably, 24(S)-
hydroxycholesterol is a natural LXR ligand 
found in the brain and elevated levels of 
24(S)-hydroxycholesterol levels are often 
associated with neuronal injury.  Our results 
are consistent with a model in which release 
of 24(S)-hydroxycholesterol,from neurons, 
can  induce the secretion of apoE-associated 
cholesterol from astrocytes.  This glial-
derived cholesterol would then be available 
for neuronal uptake during the process of 
dendritic and axonal extension and 
regeneration of synapses (26)  
Because the potent synthetic LXR 
agonist GW683965A also induced apoE, 
ABCA1, and ABCG1 mRNA expression in 
astrocyte-derived cells, our results suggest 
that 24(S)-hydroxycholesterol mediates its 
action through LXR activation. Furthermore, 
differential expression of the nuclear 
hormone receptor LXR isoforms, i.e. LXR 
and , between astrocytoma and 
neuroblastoma cells may also account for 
the difference in sensitivity to these agonists 
between astrocytic and neuronal cells. Our 
results suggest that 24(S)-
hydroxycholesterol-mediated induction of 
ABCG1 and ABCA1 primes the astrocytes 
to deliver cholesterol to apoE or apoA-I, 
since their expression was robustly induced 
by both compounds. In neuroblastoma cells, 
neither of the two compounds stimulated 
apoE-mediated cholesterol efflux, but both 
compounds induced apoA-I-mediated 
cholesterol efflux, probably involving 
ABCA1 actions.  
It has been proposed that, after 
differentiation of astrocytes, neurons reduce 
their endogenous cholesterol synthesis and 
rely predominantly on cholesterol delivery 
by astrocytes via lipoprotein-like particles 
that contain astroglia-derived apoE (47). 
Cholesterol delivery may, at least in part, 
participate in regulating the number of 
synapses being formed (42). A continuous 
turnover of cholesterol in neurons facilitates 
the cells ability for efficient and quick 
adaptation of cholesterol homeostasis, 
required for dynamic structural changes of 
neurons, their extensions, and their synapses 
during synaptic plasticity (43). Conversion 
of cholesterol into 24(S)-
hydroxycholesterol, which is also a brain 
specific LXR-ligand, by CYP46 represents a 
major route for cholesterol turnover in 
neurons (44).  
A common feature that astrocytes 
share with macrophages and adipocytes is 
their large content of free cholesterol 
(45,46). In agreement with what has been 
reported for macrophages (47) we found that 
activation of LXR by 24(S)-
hydroxycholesterol or GW683965A 
stimulates cellular cholesterol efflux through 
the coordinated regulation of ABCA1, 
ABCG1 and apoE. Some aspects of these 
pathways may be specific to astrocytes 
however, because apoD was unresponsive to 
LXR agonists in astrocytes whereas it is 
induced in adipocytes  (48).  
GW683965A upregulated the 
expression of HMGCoA-R, LDLR and 
SREBP2 in astrocytoma cells, supposedly to 
maintain cellular cholesterol homeostasis 
during excessive loss by efflux. However, 
24(S)-hydroxycholesterol down-regulated 
the expression of these genes. It is known 
since long that oxysterols reduce the activity 
of HMGCoA-R and are more potent 
inhibitors of cholesterol synthesis than 
cholesterol (49). However, the mechanisms 
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by which cholesterol and oxysterols reduce 
cholesterol synthesis differ (50). Cholesterol 
directly interferes with SREBP cleavage 
activating protein (SCAP), inducing a 
conformational change that prevents the 
processing of SREBP to its active form. 
Oxysterols have similar effects without 
directly interacting with SCAP. Thus, 24(S)-
hydroxycholesterol may not exert its effect 
exclusively via the LXR pathway. The 
observation that 24(S)-hydroxycholesterol, 
but not GW683965A, enhanced the 
expression of ABCG4 in neurons suggesting 
that LXR-independent pathways may be 
involved. Apparently, cholesterol efflux 
from astrocytes is not directly driven solely 
by the rate of cholesterol biosynthesis as 
afflux was induced to a similar level by 
24(S)-hydroxycholesterol and GW683965A. 
A concomitantly enhanced cholesterol 
efflux, upregulation of ABCA1 and ABCG1 
and impaired synthesis of cholesterol has 
recently also been reported as a consequence 
of statin-treatment in macrophages (47). 
Numerous studies have 
demonstrated that ABCA1 is necessary for 
the efflux of cellular cholesterol to lipid-
poor apoA-I (51). Recently, ABCA1 was 
found to facilitate the efflux of CNS 
cholesterol to apoE as the absence of 
ABCA1 compromised apoE secretion from 
both astrocytes and microglia. In addition 
apoE that is present in the CSF of ABCA1-
deficient animals is poorly lipidated (38,52). 
In contrast to ABCA1, ABCG1 and ABCG4 
are thought to facilitate the efflux of 
cholesterol to HDL, rather than to lipid-poor 
apolipoproteins (53,54).  A relationship 
between ABCG1 and the secretion of apoE 
was suggested by the observation that 
treatment of macrophages with antisense 
oligonucleotides to ABCG1 decreased the 
efflux of cholesterol and phospholipids to 
HDL and, surprisingly, also the secretion of 
apoE (53,55). Although ABCG1 and 
ABCG4 may function both as homodimers 
and heterodimers (56,57), expression of 
ABCG1 and ABCG4 overlaps in some but 
not all tissues assayed (54), which may 
indicate different functions in different 
tissues. The expression of ABCG4 appears 
to be largely restricted to nervous tissue 
(56). Our results strongly suggest that apoA-
I-mediated cholesterol efflux from 
astrocytes involves ABCA1 and that apoE 
mediates cholesterol efflux via ABCG1 and 
possibly also ABCA1, but not via ABCG4. 
Although 24(S)-hydroxycholesterol also 
stimulated apoE synthesis and secretion 
from astrocytic cells, it remains to be 
established why 24(S)-hydroxycholesterol 
treated resulted in observable cholesterol 
efflux only in the presence of exogenous 
apoE or apoA-1. A possible explanation 
may be that the levels of endogenous apoE 
secreted from 24(S)-hydroxycholesterol-
treated cells is >100 fold lower than the 
concentrations of exogenous apoE added as 
a lipid acceptor under our experimental 
conditions.  Alternatively, endogenously 
secreted apoE may already be lipidated and 
thereby act a less efficient cholesterol 
acceptor. 
Neurons are thought to dispose their 
cholesterol by conversion into 24(S)-
hydroxycholesterol, which is more polar 
than cholesterol and as a result may easily 
traverse the BBB and perhaps the neuronal 
plasma membrane itself (4). However, how 
oxysterols are transported across membranes 
and through the intracellular water phase is 
not yet known. The selective upregulation of 
ABCG4 in neuroblastoma cells by 24(S)-
hydroxycholesterol suggests a possible role 
for this transporter in oxysterol transport. 
Both 24(S)-hydroxycholesterol and also 
GW683865A enhanced apoA-I-mediated 
cholesterol efflux from neuronal cells, 
suggesting this is another neuronal pathway 
to dispose of cholesterol. However, 
GW683965A had only a limited effect on 
ABCA1 expression in these cells. Rebeck et 
al. (57) recently reported upregulation of 
neuronal ABCA1 expression by the 
synthetic LXR ligand T0901317. A role for 
apoA-I in the disposal of cholesterol from 
neurons is in line with its well-known role in 
so called "reverse cholesterol transport". 
ApoA-I is present in brain and in 
cerebrospinal fluid, and has been detected in 
senile plaques in AD patients (58,59). So far 
apoA-I synthesis within the brain has only 
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been ascribed to endothelial cells of the 
blood brain barrier (60). It remains to be 
established why 24(S)-hydroxycholesterol 
does not alone, but only in concert with 
apoE or apoAI, increase cholesterol efflux 
from astrocytes. A possible explanation may 
be the relatively small amounts (<100-fold) 
of apoE that are secreted by the cells in 
comparison with amount of apoE that is 
added as cholesterol acceptor. Alternatively, 
secreted apoE may be lapidated and thereby 
become a less efficient cholesterol acceptor. 
LXR isoforms differ in their pattern 
of expression (61). In the brain LXR levels 
are 2-5 fold higher than in the liver, while 
LXR levels are 3.5-14 fold lower than in 
the liver. (62-64). However, 24(S)-
hydroxycholesterol and GW683965A 
upregulated LXR but not LXR expression 
in astrocytoma cells (data not shown), 
similar to what has been reported for 
macrophages and adipocytes, but not liver 
and muscle (65,66). These results suggest 
the possibility that the autoregulation of 
LXR that has been suggested to occur in 
adipocytes to coordinate expression of target 
genes such as APOE (66) may also occur in 
brain. 
In conclusion, our results provide 
evidence indicating that 24(S)-
hydroxycholesterol acts as a signalling 
molecule that induces the apoE-mediated 
cholesterol efflux from astrocytes, but not 
from neurons (Fig. 9). Our findings also 
suggest a role for ABCA1 and ABCG1 in 
mediating cholesterol efflux from astrocytes. 
Thus, in the intact brain, 24(S)-
hydroxycholesterol derived from neurons 
may signal astrocytes to increase production 
of lipidated apoE particles in order to supply 
neurons with additional cholesterol during 
synaptogenesis or neuritic remodelling. 
Moreover alterations in the transcriptional 
regulation role of 24(S)-hydroxycholesterol 
on apoE-mediated cholesterol efflux may 
affect the progression of neurodegenerative 
diseases including AD. 
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FIGURE LEGENDS 
 
Figure 1. Concentration dependent effect of 24(S)-hydroxycholesterol on apoE mRNA levels 
in CCF-STTG1 and SH-SY-5Y cells, and primary rat astrocytes. Cells were incubated with 
increasing concentrations of 24(S)-hydroxycholesterol and 4 μM of GW683965A compound for a 
period of 72 hours. Total RNA was prepared from cells. Expression levels of apoE in astrocytoma 
and neuroblastoma cells (A) and rat primary astrocytes (B) were determined by QRT-PCR and 
expressed as relative gene expression to 18S. Values represent the mean ± S.D., n=4 in all groups. 
 
Figure 2. Time-dependent effect of 24(S)-hydroxycholesterol and GW683965A on apoE and 
SREBP1c expression in CCF-STTG1 cells. Cells were incubated in the presence of 10 μM 
24(S)-hydroxycholesterol () or 4 μM GW683965A () for increasing periods of time. Total 
RNA was prepared from cells. Expression levels of apoE (A) and SREBP1c (B) were determined 
by QRT-PCR and expressed as relative gene expression to 18S. Representative examples of 3 
independent experiments are shown. 
 
Figure 3. 24(S)-hydroxycholesterol and GW683965A increase apoE protein levels and apoE 
secretion in CCF-STTG1 cells. 24(S)-hydroxycholesterol upregulates apoE protein levels in 
murine primary glial cultures. CCF-STTG1 cells were treated either with increasing 
concentrations of 24(S)-hydroxycholesterol (A) and GW683965A (C) for a period of 72 hours, or 
with 10μM of 24(S)-hydroxycholesterol (B) and 4μM of GW683965A (D) for increasing periods 
of time. Conditioned medium was collected after the treatment of CCF-STTG1 cells with 
different concentrations of 24(S)-hydroxycholesterol and GW683965A for a period of 48 hours 
(E). Murine primary glial cultures were treated with increasing concentrations of 24(S)-
hydroxycholesterol for 24 hours (F). Cell lysates and medium concentrates were subjected to 
Western blot analysis as described in Experimental Procedures. ApoE expression was measured 
using a polyclonal antibody against apoE. Bands were quantified by densitometry, normalized to 
Glutamine Synthetase (GS) and GADPH. Representative experiments out of at least 3 
independent experiments are shown. 
 
Figure 4. Comparison of the basal expression of apoE, LXR , LXR , SREBP1c and   
SREBP-2 in CCF-STTG1 and SH-SY-5Y cells, and in rat primary astrocytes. Cells were 
incubated for 72 hours in DMEM/HAMF12 (1:1) medium containing 10% FCS. Total RNA was 
prepared from cells. Expression levels of apoE, LXR, LXR, SREBP1c and SREBP2 in CCF-
STTG1 and SH-SY-5Y cells (A) and rat primary astrocytes (B) were determined by QRT-PCR 
and expressed as relative gene expression to 18S. Values represent the mean ± S.D., n=4 in all 
groups. Mann-Whitney U-test was used to determine significant differences in gene expression. * 
represents  p < 0.01. 
 
Figure 5. 24(S)-hydroxycholesterol is a stronger regulator of apoE synthesis in CCF-STTG1 
cells than retinoic acid and cholesterol. 
Western blot analysis of CCF-STTG1 (A) and SH-SY-5Y (B) cell lysates and conditioned 
medium from CCF-STTG1 cells (C) that were incubated for 72 hours in the presence of either 10 
μM 24(S)-hydroxycholesterol, 22-(R)-hydroxycholesterol, 9-cis-retinoic acid (RA), free 
cholesterol (FC) or 4 μM GW683965A. Bands were quantified by densitometry, normalized to 
Glutamine Synthetase (GS) and GADPH. Representative experiments are shown; at least 3 
independent experiments were performed for all conditions. 
 
Figure 6. Effect of 24(S)-hydroxycholesterol and GW683965A on mRNA levels of ATP-
binding cassette transporters in CCF-STTG1 and SH-SY-5Y cells, and rat primary 
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astrocytes. (A) Represents a basal gene expression of ATP-binding cassette transporters in CCF-
STTG1 and SH-SY-5Y cells and (B) in rat primary astrocytes. Total RNA was prepared from the 
cells as described in Experimental Procedures. Gene expression relative to 18S was determined 
by QRT-PCR. Mann-Whitney U-test was used to determine significant differences in gene 
expression. A “*” indicates that p < 0.01. Astrocytoma and neuroblastoma cells (C), (F), (H) and 
rat primary astrocytes (D), (G), (I) were incubated for 72 hours in the presence of 1, 5 or 10 μM 
24(S)-hydroxycholesterol or in the presence of 4 μM GW683965A. Total RNA was prepared 
from the cells as described in Experimental Procedures. Gene expression of ABCA1 (C), (D), 
ABCG1 (F), (G) and ABCG4 (H), (I) relative to 18S was determined by QRT-PCR.   Protein 
levels of ABCA1 in whole lysates of primary mixed glial cultures treated with increasing 
concentrations of 24(S)-hydroxycholesterol for a period of 24 hours were determined by Western 
blot and quantified by densitometry. Intracellular GAPDH was used as an internal protein loading 
control (E). Data represent the mean and standard deviation of cellular ABCA1 levels. One-way 
ANOVA with Newman-Keuls post-test was used to determine significant differences (* 
represents p<0.01 compared to vehicle only). 
 
Figure 7. Time dependent effect of 24(S)-hydroxycholesterol and GW683965A on 
expression of SREBP2 (A), LDLR (B), HMGCoA-R (C) in CCF-STTG1 cells. CCF-STTG1 
cells were incubated in the presence of 10 μM 24(S)-hydroxycholesterol () or 4 μM 
GW683965A () for increasing periods of time. Total RNA was prepared from cells and gene 
expression relative to 18S was determined by QRT-PCR.   
 
Figure 8. 24(S)-hydroxycholesterol and GW683965A induce apoE- and apoAI-mediated 
cholesterol efflux from CCF-STTG1 cells, but not from SH-SY-5Y cells. After loading the 
cells with [3H] cholesterol for 24 hours, the apoE- or apoA-I mediated cholesterol efflux over a 
period of 20 hours from CCF-STTG1 cells (A) and SH-SY-5Y cells (B) was determined. [3H] 
cholesterol was quantified in medium and in cell extracts. Values are the mean ± S.D. of three 
independent experiments each measured in duplicate. Student's t test was used to determine 
significant differences of cholesterol efflux levels. * represents  p < 0.05 and ** represents p < 
0.001.  
 
 
Figure 9. Schematic presentation of the differential effects in astrocytes and neurons of 
24(S)-hydroxycholesterol on the expression of apoE and ABC transporters expression, as 
well as apoE-mediated cholesterol efflux. 24(S)-hydroxycholesterol upregulates apoE synthesis, 
as well as apoE-mediated cholesterol efflux in astrocytes, but not in neurons. Upregulation of 
ABCA1 and ABCG1 in astrocytes by 24(S)-hydroxycholesterol suggests involvement of these 
transporters in the efflux of cholesterol.  
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